

S3 Table. AGR3 expression and pathological features in IDC patients of grade III

Pathological feature	No.	AGR3 expression, n (%)		r_s	p-value
		Low	High		
Age (yr)				-0.041	0.760
< 50	25	19 (76.0)	6 (24.0)		
≥ 50	34	27 (79.4)	7 (20.6)		
Tumor size (cm) ^{a)}				0.144	0.278
< 2	11	11 (100)	0		
2-5	44	31 (70.5)	13 (29.5)		
> 5	4	4 (100)	0		
Lymph node metastases				0.083	0.718
0	25	21 (84.0)	4 (16.0)		
1-3	17	12 (70.6)	5 (29.4)		
4-9	11	8 (72.7)	3 (27.3)		
>9	6	5 (83.3)	1 (16.7)		
Distant metastasis				0.184	0.163
No	45	37 (82.2)	8 (17.8)		
Yes	14	9 (64.3)	5 (35.7)		
Estrogen receptor ^{a)}				0.214	0.185
Negative	30	26 (86.7)	4 (13.3)		
Positive	29	20 (69.0)	9 (31.0)		
Progesterone receptor ^{a)}				0.050	0.707
Negative	30	24 (80.0)	6 (20.0)		
Positive	29	22 (75.9)	7 (24.1)		
HER2 status ^{a)}				0.065	0.888
- to +	44	35 (79.5)	9 (20.5)		
++ to +++	15	11 (73.3)	4 (26.7)		
Ki-67 ^{a)}				-0.036	1.000
Negative	12	9 (75.0)	3 (25.0)		
Positive	47	37 (78.7)	10 (21.3)		
Recurrence or distant metastasis ^{a)}				0.108	0.658
No	45	36 (80.0)	9 (20.0)		
Yes	13	9 (69.2)	4 (30.8)		

AGR3, anterior gradient 3; IDC, invasive ductal carcinoma; HER2, human epidermal growth factor receptor 2. ^{a)}Some missing data; p-value was calculated by Spearman's rank-correlation test.